
Opinion|Videos|June 5, 2025
Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
Panelists discuss how standardized toxicity grading for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome helps guide physicians in the timely management and escalation of care, emphasizing the importance of symptom grading and clear institutional protocols for intervention.
Advertisement
Episodes in this series

Summary for Physicians:
Standardized Toxicity Grading: Cytokine Release Syndrome (CRS) and Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS)
- CRS:
- Grade 1: Fever, mild symptoms, manageable with supportive care
- Grade 2: Moderate symptoms (eg, hypotension, hypoxia), requires intervention (eg, intravenous fluids, antipyretics)
- Grade 3: Severe symptoms (eg, multiorgan involvement), requires corticosteroids and tocilizumab
- Grade 4: Life-threatening, requires intensive care unit (ICU) care and urgent interventions
- ICANS:
- Grade 1: Mild symptoms (eg, confusion, agitation), no intervention needed
- Grade 2: Moderate symptoms, requires steroids or other interventions
- Grade 3: Severe symptoms (eg, encephalopathy, seizures), may require ICU and immunosuppressive therapy
- Grade 4: Life-threatening, requires intensive care and urgent interventions
Institutional Protocols:
- Prompt grading of symptoms is essential for early intervention.
Clear escalation protocols for managing CRS and ICANS, with specific guidance for steroid administration, monitoring, and ICU transfer if necessary.
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5

